Jennison Associates
OCUL icon

Jennison Associates’s Ocular Therapeutix OCUL Stock Holding History

Jennison Associates’s Portfolio OCUL Stock Details OCUL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$614K Buy
+72,511
New +$691K ﹤0.01% 537
2019
Q2 		– Sell
-252,708
Closed -$1M – 667
2019
Q1 		$1M Sell
252,708
-1,379,938
-85% -$5.55M ﹤0.01% 541
2018
Q4 		$6.5M Sell
1,632,646
-703,343
-30% -$3.88M 0.01% 467
2018
Q3 		$16.1M Buy
2,335,989
+16,734
+0.7% +$105K 0.01% 425
2018
Q2 		$15.7M Buy
2,319,255
+26,503
+1% +$182K 0.02% 430
2018
Q1 		$14.9M Buy
2,292,752
+297,984
+15% +$1.68M 0.01% 428
2017
Q4 		$8.88M Buy
1,994,768
+20,132
+1% +$103K 0.01% 471
2017
Q3 		$12.2M Sell
1,974,636
-10,860
-0.5% -$69.9K 0.01% 461
2017
Q2 		$18.4M Sell
1,985,496
-1,231,385
-38% -$11.9M 0.02% 420
2017
Q1 		$29.9M Hold
3,216,881
– – 0.03% 363
2016
Q4 		$26.9M Buy
3,216,881
+212,360
+7% +$1.65M 0.03% 371
2016
Q3 		$20.6M Buy
3,004,521
+31,915
+1% +$195K 0.02% 405
2016
Q2 		$14.7M Buy
2,972,606
+1,643,261
+124% +$16.3M 0.02% 437
2016
Q1 		$12.8M Buy
1,329,345
+648,468
+95% +$4.91M 0.01% 442
2015
Q4 		$6.38M Sell
680,877
-89,355
-12% -$965K 0.01% 506
2015
Q3 		$10.8M Buy
770,232
+3,953
+0.5% +$79.4K 0.01% 504
2015
Q2 		$16.1M Buy
766,279
+627,861
+454% +$15.6M 0.01% 480
2015
Q1 		$5.81M Buy
+138,418
New +$4.55M 0.01% 513

Other funds holding OCUL

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
SR
Summer Road West Palm Beach, Florida $142M AUM 43.61% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

Jennison Associates's OCUL Position: Q1 2026 in Review

Jennison Associates opened a new position in Ocular Therapeutix (OCUL) in Q1 2026: 72,511 shares worth $614K. The stake represents ﹤0.01% of the portfolio and ranks #537 among its holdings. This is a return to the name: Jennison Associates previously reported a position in OCUL as recently as Q1 2019.

Jennison Associates first reported a position in OCUL in Q1 2015 and has held it in 18 quarters since. The position peaked at $29.9M in Q1 2017. 269 funds tracked by Wall St. Rank hold OCUL as of Q1 2026.

  • Jennison Associates held 72,511 shares of Ocular Therapeutix worth $614K as of Q1 2026.
  • Ocular Therapeutix was a new Jennison Associates position in Q1 2026.
  • Ocular Therapeutix made up ﹤0.01% of Jennison Associates's portfolio in Q1 2026, its #537 holding.
  • Jennison Associates first reported a position in Ocular Therapeutix in Q1 2015 and has held it in 18 quarters since.
  • Jennison Associates's Ocular Therapeutix position peaked at $29.9M in Q1 2017.
  • 269 funds tracked by Wall St. Rank held Ocular Therapeutix as of Q1 2026.

Based on Jennison Associates's 13F filing for Q1 2026, filed 6 May 2026.